Corin moves into spinal disc nucleus market
This article was originally published in Clinica
Aimed at expanding the company's presence within the non-fusion spinal device market, UK orthopaedics firm Corin has joined forces with a UK consortium to help develop an artificial disc nucleus device for use in spinal surgery.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.